Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorGAUDET, Camille
dc.contributor.authorODET, Stephane
dc.contributor.authorMEYER, Christophe
dc.contributor.authorCHATELAIN, Brice
dc.contributor.authorWEBER, Elise
dc.contributor.authorPARMENTIER, Anne-Laure
dc.contributor.authorDERRUAU, Stephane
dc.contributor.authorLAURENCE, Sebastien
dc.contributor.authorMAUPRIVEZ, Cedric
dc.contributor.authorBRENET, Esteban
dc.contributor.authorKERDJOUDJ, Halima
hal.structure.identifierBioingénierie tissulaire [BIOTIS]
dc.contributor.authorFENELON, Mathilde
hal.structure.identifierBioingénierie tissulaire [BIOTIS]
dc.contributor.authorFRICAIN, Jean-Christophe
dc.contributor.authorZWETYENGA, Narcisse
dc.contributor.authorHOARAU, David
dc.contributor.authorCURIEN, Remi
dc.contributor.authorGERARD, Eric
dc.contributor.authorLOUVRIER, Aurelien
dc.contributor.authorGINDRAUX, Florelle
dc.date.accessioned2023-02-21T13:18:42Z
dc.date.available2023-02-21T13:18:42Z
dc.date.issued2022-12
dc.identifier.issn2073-4409en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/172018
dc.description.abstractEnMedication-related osteonecrosis of the jaw (MRONJ) is a complication caused by anti-resorptive agents and anti-angiogenesis drugs. Since we wanted to write a protocol for a randomized clinical trial (RCT), we reviewed the literature for the essential information needed to estimate the size of the active patient population and measure the effects of therapeutics. At the same time, we designed a questionnaire intended for clinicians to collect detailed information about their practices. Twelve essential criteria and seven additional items were identified and compiled from 43 selected articles. Some of these criteria were incorporated in the questionnaire coupled with data on clinical practices. Our review found extensive missing data and a lack of consensus. For example, the success rate often combined MRONJ stages, diseases, and drug treatments. The occurrence date and evaluation methods were not harmonized or quantitative enough. The primary and secondary endpoints, failure definition, and date coupled to bone measurements were not well established. This information is critical for writing a RCT protocol. With this review article, we aim to encourage authors to contribute all their findings in the field to bridge the current knowledge gap and provide a stronger database for the coming years.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enanti-angiogenic
dc.subject.enbisphosphonates
dc.subject.enbone healing
dc.subject.enconsensus
dc.subject.endenosumab
dc.subject.enoral mucosa
dc.subject.enosteonecrosis
dc.subject.entools
dc.title.enReporting Criteria for Clinical Trials on Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review and Recommendations
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/cells11244097en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
bordeaux.journalCellsen_US
bordeaux.volume11en_US
bordeaux.hal.laboratoriesBioingénierie Tissulaire (BioTis) - U1026en_US
bordeaux.issue24en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionCHU de Bordeauxen_US
bordeaux.institutionInstitut Bergoniéen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03998986
hal.version1
hal.date.transferred2023-02-21T13:18:59Z
hal.exporttrue
dc.rights.ccCC BYen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cells&rft.date=2022-12&rft.volume=11&rft.issue=24&rft.eissn=2073-4409&rft.issn=2073-4409&rft.au=GAUDET,%20Camille&ODET,%20Stephane&MEYER,%20Christophe&CHATELAIN,%20Brice&WEBER,%20Elise&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée